CLL patient-derived neoplastic cells exhibited significantly higher CD36 levels than normal CD19+ B-cells; these CLL cells in culture, owing to a STAT3-driven metabolic adaptation, were able to metabolize FFAs in the cell medium [359]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.